There's a little-known fact in cardiology: Most of the care that's provided doesn't prevent heart attacks.
Consider the following sobering statistics, all backed by clinical research:
90% of stress tests come back with normal results
75% of the lesions responsible for heart attacks cause only mild narrowing of the arteries, which conventional stress tests cannot pick up
70% of patients who have a heart attack are considered low risk by traditional measures
66% of referrals to catheterization labs for invasive evaluations of the heart are unnecessary
For too long, cardiovascular care has focused primarily on symptoms while failing to address the root cause of heart disease. Our Transforming Cardiac Care webinar series offers candid conversations with the world's leading experts on using CCTA to identify at-risk patients and provide the most effective preventive and precision heart care.
Why is this the case?
For years – decades, even – research paper after research paper has demonstrated the utility of product or service X to find Y number of patients who have experienced Z symptoms.
The flaw here is the focus on the symptoms at a population level. Hypertension, high cholesterol, or diabetes are risk factors but not causes of heart disease. This false dichotomy sends cardiovascular care in the wrong direction. It leads millions of "high-risk" patients to receive care they don't need while "low-risk" patients go unnoticed and untreated, only to present at the emergency department with an unexpected heart attack.
The root cause of a heart attack is atherosclerosis or the buildup of arterial plaque. That can only be determined at an individual level, using a combination of coronary computed tomography angiography (CCTA) to capture images of arterial plaque and advanced analytics to determine the type, extent, and severity of plaque and inform the best course of treatment.
Cardiology hasn't focused on personalized, preventive, precision care. It's time to change that.
To talk about how the industry can make this change – and how it won't disrupt existing cardiology business models in the hospital or independent practice – Cleerly is hosting a Transforming Cardiac Care webinar series with several of the world's leading experts on leveraging CCTA to proactively identify the right patients and provide them with the most effective therapies to slow the progression of heart disease and prevent a heart attack from happening.
Along with our guest speaker, each webinar will feature Cleerly Chief Executive Officer James K. Min, M.D., and Cleerly Chief Medical Officer James Earls, M.D. Over the course of the webinar series, we'll take a deep dive into those sobering statistics and answer a key question about how we as an industry can change the paradigm for cardiovascular care.
Here's a quick look at the first installments of the Transforming Cardiac Care webinar series.
STAGING ATHEROSCLEROSIS: UNDERSTANDING PLAQUE BURDEN FOR PATIENT EVALUATION AND TREATMENT
Andrew Freeman, MD, FACC, is Director of Cardiovascular Prevention and Wellness at National Jewish Health. He uses advanced cardiovascular diagnostics and lifestyle medicine in his approach to wellness and disease prevention.
In the second webinar of the Transforming Cardiac Care series, Dr. Freeman will discuss the industry's first novel, four-tiered atherosclerotic plaque staging system. He'll explain how plaque staging can support more precise treatment based on an individual's atherosclerotic phenotype.
Staging Atherosclerosis: Understanding Plaque Burden for Patient Evaluation and Treatment will take place May 25 at 2 p.m. Eastern time. Register here.
What is the Driving Force Behind Increased Heart Attack Risk?
Daniele Andreini, M.D. is an associate professor of cardiovascular disease at Milan's Centro Cardiologico Monzino. He is involved in nearly 20 international studies involving CCTA analysis. One such study, INTESTRAT-CAD, explores the possibility of predicting whether a patient with atherosclerosis will develop an acute myocardial infarction based on the results of a CT scan and biomarkers in the blood.
In the first webinar of the Transforming Cardiac Care series, Dr. Andreini explains why traditional methods of evaluating heart disease aren't working and why atherosclerosis is the strongest predictor of future heart attack risk. He discusses how CCTA can be used to track the way that plaque changes over time – a critical factor in determining whether medical therapies or lifestyle interventions will succeed in preventing a future heart attack.
At Cleerly, we are transforming heart disease and creating a new standard of precision heart care. Join our webinar series for conversations on a paradigm shirt in heart disease evaluation and treatment.